Established in 2008, Cardialen, Inc., set out to develop an implantable defibrillation therapy using low-electrical energy designed to more gently restore normal heart rhythm and potentially avoid the negative side-effects of current therapies.

For more information, visit CardiaLen or follow their updates on:


  • $34m

CardiaLen Articles

Dollar sign fundraising

12 Fundraising Tips for BioTech Companies from Cultivation Capital’s Life Sciences Fund

2015 St. Louis Capital Report: Brian Matthews Outlines Funding From Angels and Venture Capitalists

Mythbusters: The Real Life of Venture-Backed CEOs

Cortex St. Louis

Cortex Announces Facilities Partnership with Wash U and SLU